Selux Diagnostics is developing technology for next generation phenotyping (NGP). NGP refers to technologies that can rapidly and accurately diagnose and prescribe patients with personalized antibiotic therapies to treat diseases such as infectious diseases. By acting faster with better-informed decisions, more lives can be saved and hospital length stays can be reduced. Selux is using their platform to deliver personalized therapy results for all patients within a day of hospital entry, speeding the targeted treatment by an average of two days. In this manner Selux is advancing their antibiotic susceptibility testing to reduce the incidence of antimicrobial resistance and preserve the power of antibiotics for future generations.

Selux Diagnostics

Manufacturing Engineer

Field Service Engineer

Microplate-based surface area assay for rapid phenotypic antibiotic susceptibility testing | Scientific Reports - Nature.com

Selux Diagnostics Announces Additional $48 Million in Funding - BioSpace

On Sunday, Selux had the pleasure of hosting Jack and Jill of America, Inc. Boston Chapter intermediate group for a day of hands-on science experiments and learning in the lab. It was an honor to share our work with these future leaders, and we can’t wait to see what they'll accomplish in the years to come.

A special thank you to Rafael Francis, Nikitha Sam, and Christina Alexander for organizing and hosting this incredible event.

#RapidAST #AntibioticResistance  #NGP #Superbugs  #SeluxDx #AllSampleTypes


            The Selux PBC Separator With Selux AST System Receives FDA 510(k) Clearance for Rapid Antibiotic Susceptibility Testing Direct From Positive Blood Culture
            10 months ago
            The Selux PBC Separator, part of the Next Generation Phenotyping (NGP) System, makes this the only FDA cleared, single-platform technology capable of delivering rapid AST results for both positive blood culture and isolated colonies.
        

Dr. James S. Lewis II, Antibiotic Susceptibility Test Expert, Joins as Chair of Selux Diagnostics’ Clinical Advisory BoardOctober 18, 2022

BD and Accelerate Diagnostics collaborate on rapid antibiotic resistance test - BioWorld Online

Did you know that the Selux AST System is the only FDA-cleared platform capable of performing rapid AST direct from positive blood culture and isolates? The single-platform technology helps boost lab efficiency by delivering results in as little as 5.5 hours, ultimately leading to faster, better patient care.

Dive into the details here: https://seluxdx.co/40xqKhg
.
.
.
#AntibioticResistance #RapidAST #NGP #Superbugs  #SeluxDx #AllSampleTypes

The Selux NGP System is a rapid phenotypic AST platform delivering results from positive blood culture and isolates in as little as 5.5 hours. Learn more about the power of Selux here: https://seluxdx.co/4esvoR2
.
.
.
#AMR #AntibioticResistance #RapidAST #NGP #Superbugs  #SeluxDx #AllSampleTypes

 SeLux leverages government support to develop rapid antibiotic susceptibility test 

This week is the WHO's World Antimicrobial Awareness Week. At Selux, it's our mission to preserve the lifesaving power of antibiotics for future generations. Check out how we're making an impact: https://seluxdx.co/3Cs0PgZ
.
.
.
#AntibioticResistance #RapidAST #NGP #Superbugs  #SeluxDx #WAAW #AntimicrobialResistance #AllSampleTypes

Careers

Selux Diagnostics Raises $50M for Next-Generation Phenotyping Platform - HIT Consultant

FDA Clears 'Selux NGP System' for Rapid ASTRead More

Customer Login

 Selux Diagnostics Announces Additional $48 Million in Funding 

 Selux Diagnostics Announces Appointment of John Wilson as Chief Commercial Officer 

 Healthcare Industry Veteran Jamie Condie Joins Selux Diagnostics' Board of Directors 

FDA Grants EUA for Combo Flu SARS-CoV-2 Home Test - Infectious Disease Special Edition

Selux is wrapping up all things antibiotic susceptibility testing (AST) for you to take with you into the new year. Check out our 2024 scientific presentations, press releases, and more below. Here’s to continuing the fight against superbugs in 2025!
 
Presentation
________________________
 
Rapid AST is here to stay: Multi-site comparison of performance and time-to-results of rapid and legacy AST Systems with “gold standard” methods: https://seluxdx.co/3VMFXrz
 
Speakers: Dr. Patricia (Trish) Simner, Johns Hopkins PhD, D(ABMM), Dr. Andrew Clark, UTSW, PhD, D(ABMM), Dr. John Fissel, TriCore Reference Laboratories, Ph.D. D(ABMM), M(ASCP)CM
 
 
Press release
________________________
 
The Selux PBC Separator With Selux AST System Receives FDA 510(k) Clearance for Rapid Antibiotic Susceptibility Testing Direct From Positive Blood Culture: https://seluxdx.co/3VLgcrP
 
#AntibioticResistance #RapidAST #NGP #Superbugs #SeluxDx

Dr. Thomas Kirn, MD, Ph.D., says that speed most definitely matters when it comes to antibiotic susceptibility testing (AST), both from a cost perspective and a clinical perspective. He highlights that shorter turnaround times (TTR) on isolates lead to better patient outcomes, shorter hospital stays, and reduced costs. Learn more about how Selux's single-platform technology supports clinicians and patients by providing rapid AST results direct from positive blood culture and isolates.

Watch Dr. Kirn's full presentation here: https://seluxdx.co/3UCHi3z
.
.
.
#AntibioticResistance #RapidAST #NGP #Superbugs  #SeluxDx #AllSampleTypes

 Selux Diagnostics, Inc’s Post 

 Selux Diagnostics Receives $8.0 Million in Additional Funding to Redefine Speed in Microbiology Laboratory Testing 

 Carrier for automated microbiology sample processing 

 ECCMID 2020 Alert: Selux Diagnostics Hosting Integrated Symposium at 30th European Congress of Clinical Microbiology & Infectious Diseases 

 Selux Diagnostics Announces Selection of Three Abstracts for Poster Sessions at ASM Microbe 2019 Conference 

Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation 'Phenotyping' (NGP) Platform for Positive Blood Culture and Sterile Body Fluid Samples - PR Newswire

The Selux PBC Separator With Selux AST System Receives FDA 510(k) Clearance for Rapid Antibiotic Susceptibility Testing Direct From Positive Blood Culture - Newswire

Selux Diagnostics Raises Additional $48M in Funding - FinSMEs

Selux secures $50M for commercialization of antimicrobial susceptibility testing platformMarch 3, 2022

Selux Diagnostics Announces Additional $50 Million in Series C Funding - PR Newswire

Selux is celebrating 10 years of combating superbugs! We're incredibly proud of the work we've done over the last decade to launch the Selux NGP System, providing rapid AST results to patients when they need it most.

#AntibioticResistance #RapidAST #NGP #Superbugs  #SeluxDx #AllSampleTypes

Diagnostic company uses tech to find specific antibiotics - Boston Herald

FDA FDA Clearance Selux Next Generation Phenotyping System NGP - Infectious Disease Special Edition

 Selux Diagnostics, Inc on LinkedIn: #antibioticresistance #rapidast #ngp #superbugs #seluxdx 

Selux Receives FDA Clearance on Their Gram-Negative PanelJune 16, 2023

Get Directions

Selux Diagnostics,

 Selux's PBC Separator obtains US FDA 510(k) clearance 

Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation ‘Phenotyping’ (NGP) Platform for Positive Blood Culture and Sterile Body Fluid SamplesSeptember 28, 2021

 System, method and interface for parallel processing of antimicrobial … 

Multicenter evaluation of the Selux Next-Generation Phenotyping antimicrobial susceptibility testing system - American Society for Microbiology

 Selux Diagnostics Scores $50M in Series C 

FDA can’t resist Selux rapid antibiotic susceptibility testing platform - BioWorld Online

 Selux Diagnostics Awarded $2.8 Million Grant from NIH for Commercialization of its NGP Platform 


            Selux Diagnostics Announces Additional $48 Million in Funding
            8 months ago
            This additional funding comes at the heels of Selux announcing their third FDA 510(k) clearance on their direct from Positive Blood Culture Separator, making them the only single-platform technology capable of delivering rapid AST results for both positive blood culture and isolated colonies.
        

Selux Diagnostics pulls in $50m Series CMarch 3, 2022

A presentation by Dr. Thomas Kirn, MD, Ph.D., "Does Speed Matter? The Financial and Clinical Impact of Rapid AST," highlights that shorter non-blood culture isolate AST turnaround times resulted in statistically significant reductions in length of stay (LOS), hospital costs, and pharmacy costs. What's arguably even more important, is that the odds of a patient being discharged to home increased. Learn more about how the the Selux AST System is the only FDA-cleared platform capable of performing rapid AST direct from positive blood culture AND isolates.

Check out his full presentation to learn more about why performing rapid AST on isolated colonies is critical to better patient care: https://seluxdx.co/3Cr5nEe
.
.
.
#AntibioticResistance #RapidAST #NGP #Superbugs  #SeluxDx #AllSampleTypes

 Selux Diagnostics, Inc on LinkedIn: #antibioticresistance #rapidast #microbiologist #microbiologytip #seluxdx 

Selux secures $50M for commercialization of antimicrobial susceptibility testing platform - BioWorld Online

 Selux Diagnostics Raises Additional $48M in Funding 

Selux Diagnostics Announces Appointment of John Wilson as Chief Commercial OfficerNovember 16, 2021

 Rapid methods for determining microorganism growth in whole blood samples 

 Sands Capital Joins $48 Million Funding Round for Selux Diagnostics 

Selux Diagnostics Announces Additional $50 Million in Series C FundingFebruary 28, 2022

Selux Diagnostics Receives Additional $14.6 Million in BARDA Funding After Successfully Completing First Clinical Trial - PR Newswire

 Performing antimicrobial susceptibility testing and related systems and methods 

 Revolutionizing Infectious Disease Care: Selux Diagnostics Wins FDA Clearance for Groundbreaking AST System 

Selux Diagnostics Awarded $2.8 Million Grant from NIH for Commercialization of its NGP PlatformOctober 19, 2021

Selux Diagnostics Announces Additional $48 Million in FundingApril 1, 2024

Grateful for the brilliant minds behind our rapid AST technology. Our Seluxors are working tirelessly to bring solutions to the fight against antimicrobial resistance (AMR).
.
.
.
#AntibioticResistance #RapidAST #NGP #Superbugs  #SeluxDx #WAAW #AntimicrobialResistance #AllSampleTypes


            Selux Diagnostics Receives FDA Clearance on Their Gram-Negative Panel, Expanding the Antibiotic Menu for Its Next Generation Phenotyping System for Rapid AST
            1 year ago
            Approval gives way to the most comprehensive single menu offered by an AST platform while delivering precise, rapid results in 5.5 hours from isolated colonies.
        

We're spreading the word, not superbugs. Selux is at the forefront of the fight against antimicrobial resistance (AMR). Learn how the Selux NGP System delivers rapid AST results that empower clinicians to make faster, more targeted treatment decisions for better patient care: https://seluxdx.co/3YT4c8k
.
.
.
#AMR #AntibioticResistance #RapidAST #NGP #Superbugs  #SeluxDx #WAAW #AntimicrobialResistance #AllSampleTypes

 Assays for improving automated antimicrobial susceptibility testing accuracy 

The Selux PBC Separator With Selux AST System Receives FDA 510(k) Clearance for Rapid Antibiotic Susceptibility Testing Direct From Positive Blood CultureFebruary 26, 2024

Selux Diagnostics

Business:

About: